Isaka M, Yasuda Y, Kozuka S, Miura Y, Taniguchi T, Matano K, Goto N, Tochikubo K
Department of Microbiology, Nagoya City University Medical School, Japan.
Vaccine. 1998 Oct;16(17):1620-6. doi: 10.1016/s0264-410x(98)00066-8.
For the purpose of changing the immunization procedure of tetanus toxoid from intramuscular or subcutaneous injection, which has been in practice for a long time, to intranasal administration, we examined systemic and mucosal immune responses of mice to aluminium-adsorbed tetanus toxoid (aTT) and aluminium-non-adsorbed tetanus toxoid (nTT) inoculated intranasally with recombinant cholera toxin B subunit (rCTB). Intranasal immunization with aTT induced, at a concentration of 0.5 Lf, high levels of TT-specific serum IgG antibody titres and moderate levels of TT-specific serum IgA antibody titres in the presence and absence of rCTB. Induction of high or moderate levels of mucosal TT-specific IgA antibody responses was observed with and without rCTB in the lung, the nasal cavity, the small and large intestines and the vagina. Generally speaking, the co-administration of aTT and rCTB showed higher mucosal TT-specific IgA antibody titres when compared with the administration of aTT alone. In case of intranasal administration of nTT, the dose of 5 Lf was necessary and stimulated, only in the presence of rCTB (10 micrograms), high levels of tetanus toxoid (TT)-specific serum IgG antibody responses in all mice examined and moderate or slight levels of TT-specific IgA antibody responses in the nasal, pulmonary and small and large intestinal lavages of a few mice. All mice intranasally immunized with aTT alone or nTT and rCTB escaped onset of tetanus. This is the first report concerned with the mucosal adjuvant activity of an aluminium compound. Judging from these results, intranasal administration of aTT with and without rCTB or nTT with rCTB appears to be a very useful means for a vaccination against tetanus with respect to ease, safety, certainty, low cost and no need for an injection needle.
为了将长期以来一直采用的破伤风类毒素肌内或皮下注射免疫程序改为鼻内给药,我们研究了小鼠对经鼻接种重组霍乱毒素B亚单位(rCTB)的吸附破伤风类毒素(aTT)和未吸附破伤风类毒素(nTT)的全身和黏膜免疫反应。在有或没有rCTB存在的情况下,用0.5Lf浓度的aTT经鼻免疫诱导出高水平的破伤风类毒素(TT)特异性血清IgG抗体滴度和中等水平的TT特异性血清IgA抗体滴度。在肺、鼻腔、小肠和大肠以及阴道中,无论有无rCTB,均观察到高水平或中等水平的黏膜TT特异性IgA抗体反应。一般来说,与单独给予aTT相比,aTT和rCTB联合给药时黏膜TT特异性IgA抗体滴度更高。在经鼻给予nTT的情况下,5Lf的剂量是必要的,并且仅在存在rCTB(10微克)时,在所检测的所有小鼠中刺激产生高水平的破伤风类毒素(TT)特异性血清IgG抗体反应,在少数小鼠的鼻腔、肺部以及小肠和大肠灌洗液中产生中等或轻微水平的TT特异性IgA抗体反应。所有单独用aTT或nTT与rCTB经鼻免疫的小鼠均未发生破伤风。这是关于铝化合物黏膜佐剂活性的首次报道。从这些结果来看,无论有无rCTB经鼻给予aTT或nTT与rCTB联合给药,在简便性、安全性确切性、低成本以及无需注射针头方面,似乎都是一种非常有用的破伤风疫苗接种方法。